AstraZeneca Given “Buy” Rating at Nordea Equity Research (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Nordea Equity Research in a research note issued to investors on Friday, Stock Ratings Network.com reports. They currently have a GBX 4,469.30 ($73.64) price target on the stock. Nordea Equity Research’s price target suggests a potential upside of 15.40% from the company’s current price.
Shares of AstraZeneca (LON:AZN) opened at 3852.5002 on Friday. AstraZeneca has a 1-year low of GBX 2895.00 and a 1-year high of GBX 3964.50. The stock has a 50-day moving average of GBX 3681. and a 200-day moving average of GBX 3370.84. The company’s market cap is £48.272 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a GBX 3,700 ($60.97) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Friday, January 24th. They now have a GBX 3,600 ($59.32) price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Tuesday, January 21st. They now have a GBX 3,112 ($51.28) price target on the stock. Twelve equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of GBX 3,369.96 ($55.53).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.